Exploring how compounds from hops can help reduce inflammation in bowel diseases.
Discovery and Biological Signatures of Microbiome-Derived Xanthohumol Metabolites and their Role in Ameliorating Inflammatory Bowel Disease
This study is looking at how a natural compound from hops called xanthohumol might help reduce inflammation in people with inflammatory bowel disease (IBD) by working with the bacteria in the gut, and patients may be asked to provide samples to help us learn more about this.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon State University NIH-funded |
| Lab location | 1 site (Corvallis, United States) |
| Project ID | NIH-10472280 on NIH RePORTER |
What this research studies
This research investigates the potential of xanthohumol, a compound derived from hops, to alleviate inflammation in patients with inflammatory bowel disease (IBD). The study focuses on understanding how xanthohumol interacts with gut microbiota and how these interactions may lead to the production of metabolites that can further reduce inflammation. By examining these biological signatures, the research aims to identify new therapeutic strategies that target both the inflamed gut and the underlying microbial imbalances. Patients may be involved in providing samples to help analyze these interactions and their effects on IBD.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are diagnosed with inflammatory bowel disease, such as Crohn's disease or ulcerative colitis.
Not a fit: Patients with non-inflammatory bowel conditions or those under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve the management of inflammatory bowel disease.
How similar studies have performed: Previous research has shown promising results with similar approaches using natural compounds to target gut inflammation, suggesting potential for success in this study.
Where this research is happening
Corvallis, United States
- Oregon State University — Corvallis, United States (Active)
Researchers
- Principal investigator: Stevens, Jan Frederik — Oregon State University
- Study coordinator: Stevens, Jan Frederik
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.